The short answer is yes: medical cannabis can interact with some other medicines, but this is not something patients need to panic about or try to solve alone. For many people, the interaction conversation is a normal part of specialist prescribing: tell the clinician what you take, and they can check what matters.
NHS patient information on medical cannabis says CBD and THC can affect how other medicines work. That is a reason to be open with the prescriber, not a reason to scare yourself with half-understood lists of possible combinations. Prescribed medical cannabis is considered alongside your condition, your current medicines, your previous side effects, your risk factors, and the reason other treatments have or have not worked for you.
This guide is not an interaction checker. It cannot tell you that a medicine combination is suitable for you, and it does not tell you to start, stop, or change anything. The aim is simpler: help you turn up with the right information so the specialist prescriber, pharmacist, or clinical team can guide you properly.
For the wider prescription pathway, read MCPH’s guide to how the medical cannabis prescription process works in the UK. For site-wide boundaries, see the MCPH medical disclaimer and editorial policy.
Why interactions matter with medical cannabis
An interaction is what happens when one medicine affects another medicine’s action, side effects, or risk profile. With medical cannabis, the main practical point is that both CBD and THC can matter, and the risk is not the same for every patient.
That does not mean every patient taking another medicine has a serious interaction risk. It means the prescriber needs to do the ordinary medicines work: look at what you take, what conditions you have, what has caused problems before, and whether anything needs monitoring. A patient taking several medicines, living with a condition that needs close monitoring, or already dealing with dizziness, tiredness, mood changes, memory issues, falls, or impairment may simply need a more careful review.
NHS medical cannabis information lists possible side effects that include tiredness, dizziness, mood or behaviour changes, feeling high, hallucinations, and suicidal thoughts. Those details are worth sharing with the clinical team, especially if another medicine also affects alertness, mood, sleep, balance, or thinking. They are not a reason to assume medical cannabis is automatically unsuitable.
There can also be monitoring questions. Some medicines need blood tests, specialist follow-up, seizure monitoring, mental health monitoring, or careful pharmacy oversight. This is normal clinical context. This guide cannot tell you how it applies to your own treatment, but it can make clear that your prescriber is the right person to assess it.
What to tell the prescriber or pharmacist
The practical version is simple: make the medicine list boringly complete.
Bring or prepare an up-to-date list of:
- prescribed medicines
- medicines bought from a pharmacy or supermarket
- supplements, herbal products, and wellness products
- any CBD, THC, or other cannabinoid products already being used
- medicines recently stopped, if they are still relevant to the consultation
- previous medicines that caused side effects or did not help
That list is not there so you can make the interaction decision yourself. It is there so the specialist prescriber or pharmacist can see the whole picture and give you a sensible answer.
It can also help to describe what has actually happened in normal language: which medicines caused problems, what side effects felt like, whether those effects affected work, sleep, driving, caring responsibilities, mood, or daily function, and whether any side effect improved after a clinician changed treatment in the past.
Keep this factual. You do not need to diagnose the interaction yourself. A clear account of what you take and what you have noticed is more useful than trying to sound medical.
Medical cannabis, unlicensed products, and specialist review
In the UK, many cannabis-based medicinal products are unlicensed medicines. That does not mean they are illegal when properly prescribed. It does mean the evidence, product governance, prescribing responsibility, and monitoring conversation need to be taken seriously.
GMC guidance says unlicensed cannabis-based medicinal products should be supplied under the prescription or direction of a doctor on the Specialist Register, working within their competence. CQC also expects providers to have appropriate specialist oversight and safe prescribing governance.
For patients, the practical point is this: interaction questions sit inside the prescribing decision. They are not an afterthought, but they are also not something you need to carry alone after reading a blog post.
NHS England guidance on cannabis-based products for medicinal use says prescribing decisions involve the patient’s clinical condition, other medicines, evidence of safety and effectiveness, patient values, and whether licensed medicines are suitable. That is a useful way to think about interactions. The question is not just “does cannabis interact with this medicine?” It is “does the whole treatment plan make sense for this patient, with these medicines and these risks?”
When interaction questions come up
Interaction questions can come up before a first prescription, during a review, or after another medicine is added.
Common moments to raise the question include:
- before a medical cannabis consultation, if you already take regular medicines
- when a prescriber suggests a cannabis-based medicinal product
- when a pharmacist asks about your current medicines
- when another clinician adds or removes a medicine
- when you buy a pharmacy medicine that can affect sleep, alertness, mood, stomach symptoms, or other side effects
- when a supplement or non-prescribed cannabinoid product is being used
- when side effects change after a treatment change
This is not a reason to panic. It is a reason to keep the clinical team informed. Interaction questions are easier to answer when the prescriber knows what is happening early, rather than finding out later after a worry or side effect has built up.
Side effects, suspected reactions, and Yellow Card reporting
Most routine interaction questions are not emergencies. They are the kind of thing to raise with the clinic, specialist prescriber, dispensing pharmacy, or another suitable healthcare professional.
If you think a medicine is causing side effects, speak to the relevant clinical team. For prescribed medical cannabis, that may be the clinic, specialist prescriber, or dispensing pharmacy, depending on the issue and the route you were given.
For life-threatening symptoms, immediate danger, severe allergic reaction, chest pain, collapse, severe breathing difficulty, or if someone is at immediate risk of harm, call 999 or go to A&E. If symptoms are urgent but not immediately life-threatening, use NHS 111 or contact an appropriate urgent care route. MCPH cannot triage symptoms, and an article cannot decide whether a medicine interaction is safe.
Suspected side effects can also be reported through the MHRA Yellow Card scheme. Yellow Card reporting is useful because it helps regulators collect safety information about medicines and medical products. It is not a replacement for clinical advice, and it is not a route for changing your medicines by yourself.
Driving and impairment need extra care
Interactions are not only about blood levels and technical pharmacy language. They can also affect how someone feels and functions.
Medical cannabis, other medicines, tiredness, dizziness, alcohol, poor sleep, and illness can all be relevant to impairment. UK drug-driving law has a specific framework for controlled drugs and prescription medicines, but this article cannot give a personal driving decision.
If driving, work safety, machinery, caring responsibilities, or alertness are relevant, raise that with the prescriber or pharmacist. The safer question is not “am I fine?” It is “what does my clinical team need to know so they can advise me properly within the law and my prescription?”
What this guide cannot do
This guide cannot:
- check your personal medicine combination
- tell you whether medical cannabis is suitable for you
- tell you whether a side effect is caused by medical cannabis or another medicine
- give dose, product, route, strain, pharmacy, or clinic advice
- tell you to start, stop, switch, reduce, increase, or combine medicines
- give driving clearance
- replace a prescriber, pharmacist, GP surgery records process, specialist clinic, or urgent medical service
That boundary is there to keep the article useful rather than frightening. A public article can explain the shape of the question. It cannot see your records, your current medicines, your monitoring needs, or the clinical reason a medicine was prescribed.
A practical way to handle the question
If you are researching medical cannabis and already take other medicines, the useful next step is not to worry yourself out of the conversation. Prepare a clear medicine list and bring interaction questions into the consultation early.
A plain version might be:
I take these medicines and supplements. Are there any interaction, side-effect, monitoring, or impairment issues you need to consider before deciding whether medical cannabis is suitable?
That keeps the decision where it belongs: with the prescriber and pharmacist, using your actual records and medicines.
Medical cannabis can be accessible for suitable patients who may benefit, often where other treatments have not worked, caused problems, or been unsuitable. Interaction questions are part of making that access safe and practical, not a warning that most people should be scared off. The goal is not just getting a prescription. It is making sure the treatment plan is clinically sensible for the person in front of the prescriber.
Next reading on MCPH
- Are there any side effects from CBD?
- How the medical cannabis prescription process works in the UK
- MCPH medical disclaimer
- MCPH editorial policy
More from the MCPH Patient Guide
Use the MCPH Patient Guide to follow the UK medical cannabis pathway in order, from eligibility and records through to safety, side effects and review questions.
Sources
- NHS: Medical cannabis
- NICE: Cannabis-based medicinal products, NG144
- NHS England: Cannabis-based products for medicinal use
- GMC: Information for doctors on cannabis-based products for medicinal use
- CQC: Cannabis-based medicinal products: what CQC expects from providers
- GOV.UK: Drug driving law
- MHRA: Yellow Card reporting site
